On video: The bill to regulate medical cannabis was passed in preliminary reading/Photo: Knesset Channel
The medical cannabis reform goes into effect on April 1st, when the health insurance clients will be able to issue a prescription instead of a license for the 10 medical labels. This is a significant relief in the procedure for receiving medical cannabis treatment.
The reform, which was postponed for three months following the war, states that the handling of issuing prescriptions and licenses for medical cannabis will be transferred to the responsibility of the health funds from the Ministry of Health. The reform states that only a prescription will be required for the following 10 indications: for oncology patients during chemotherapy or radiation treatments; patients with inflammatory bowel disease; multiple sclerosis patients; Parkinson's patients; Tourette's Syndrome; AIDS patients; epilepsy; Autism spectrum disorder; dementia; Terminally ill patients. In situations of post-traumatic stress disorder (PTSD), pain and other medical conditions, a license will be required, with the license and prescription issued through the health insurance fund.
Treatment fee for issuing a prescription: 180 NIS, rate for issuing a license 360 NIS (the rates were determined by the Ministry of Health).
From the beginning of April - significant relief in the procedure for receiving treatment. Medical Cannabis/ShutterStock
Klalit reported that it was prepared for the implementation of the reform and the provision of the service through "Mor", a subsidiary of Klalit, which will manage the procedure of issuing the prescription or license for Klalit patients after they have received a recommendation or referral for medical cannabis treatment from a specialist in his field.
From the moment the patient receives a recommendation from a specialist in his field for the treatment of medical cannabis, the patient will submit an application in the digital system established by Moore. Upon submission, it is forwarded for processing with a commitment to a quick response of up to 5 days. Holders of a valid license who are supposed to switch to a prescription route from a doctor can choose to switch to a prescription route as of April 1 or when their license expires.
According to Eli Cohen, CEO of Klalit: "Israel is among the leading countries in regulating the treatment of medical cannabis. The goal of the reform is to ease the existing regulation in the field while maintaining the health of the patients and the safety of the treatment. Our goal is to make the process easier for Klalit's patients, who make up about half of all medical cannabis license holders."
More on the same topic:
Cannabis
Medical Cannabis
drugs
Al-Sam
reform
Clalit Health Services
Ministry of Health